Annette Brüls joined Edwards as corporate vice president, Europe, Middle East, Africa, Canada, and Latin America (EMEACLA), in August 2024. Prior to joining the company, Brüls was the chief executive officer (CEO) of Medela, a leading breast pump brand and medical device manufacturer.
Previously, Brüls held several senior leadership positions at Medtronic including president of the diabetes service and solutions division, general manager of the diabetes western Europe and Canada division and vice president of marketing for cardiac rhythm disease management. She also served as vice president of marketing at Abbott Vascular for the EMEA region.
Brüls has more than 25 years of experience leading diverse teams with a mission-driven approach, coupled with a passion for innovation and technology. She has been named among the Top 50 Technology CEOs (ranked ninth) by The Health Technology Report and Best CEO for 2020, 2021, and 2022 by Comparably. As an advocate for diversity and inclusion, she is personally dedicated to elevating women in the workplace.
Since 2021, Brüls has served on the board of Coloplast, where she is a member of the compensation and nominating committee.
She holds a bachelor’s in engineering and a master’s in electrical engineering from the University of Liège’s Ecole Polytechnique, Belgium and completed additional management courses at Wharton and Harvard Business School.
What is Annette Brüls' net worth?
The estimated net worth of Annette Brüls is at least $1.56 million as of August 28th, 2026. Ms. Brüls owns 17,984 shares of Edwards Lifesciences stock worth more than $1,555,005 as of October 15th. This net worth estimate does not reflect any other assets that Ms. Brüls may own. Learn More about Annette Brüls' net worth.
How do I contact Annette Brüls?
Has Annette Brüls been buying or selling shares of Edwards Lifesciences?
Annette Brüls has not been actively trading shares of Edwards Lifesciences during the last quarter. Most recently, Annette Brüls sold 2,644 shares of the business's stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a transaction totalling $237,907.12. Following the completion of the sale, the vice president now directly owns 17,984 shares of the company's stock, valued at $1,618,200.32. Learn More on Annette Brüls' trading history.
Who are Edwards Lifesciences' active insiders?
Edwards Lifesciences' insider roster includes Donald Bobo, Jr (VP), Annette Brüls (Corporate Vice President, EMEACLA Regions), Daveen Chopra (VP), Kieran Gallahue (Director), Leslie Heisz (Director), Jean-Luc Lemercier (VP), Daniel Lippis (VP), Wayne Markowitz (General Manager and Senior Vice President, Surgical Structural Heart), Martha Marsh (Director), Michael Mussallem (CEO), Robert Sellers (VP), Catherine Szyman (VP), Scott Ullem (CFO), Nicholas Valeriani (Director), Huimin Wang (VP), Larry Wood (VP), and Bernard Zovighian (VP). Learn More on Edwards Lifesciences' active insiders.
Are insiders buying or selling shares of Edwards Lifesciences?
In the last year, insiders at the medical research company sold shares 29 times. They sold a total of 194,504 shares worth more than $16,289,081.65. The most recent insider tranaction occured on October, 8th when VP
Daniel J. Lippis sold 619 shares worth more than $53,017.35. Insiders at Edwards Lifesciences own 0.3% of the company.
Learn More about insider trades at Edwards Lifesciences. Information on this page was last updated on 10/8/2026.
